Orum Therapeutics
Business Services · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
20 Acorn Park Dr, Cambridge, Massachuset...Phone Number
+82 427163030Website
www.orumrx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
2
2
1
1
1
About Orum Therapeutics
Orum Therapeutics is a clinical stage biotech company focused on pioneering a novel class of antibody-drug conjugates (ADCs) through their innovative protein degrader technology. Their approach aims to enhance the efficacy, safety, and half-life of conventional targeted protein degraders. The company is dedicated to expanding the landscape of druggable targets with a portfolio of differentiated products. Orum Therapeutics targets clients in the pharmaceutical and biotechnology sectors, seeking to revolutionize disease treatment.Explore more
Orum Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Orum Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Orum Therapeutics is spiking on competitors!
Check if Orum Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Orum Therapeutics launches new products
Orum Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Orum Therapeutics
Earning: See what the market has to say on Orum Therapeutics recently announced quarterly report
Funding: Get notified immidiatlly once Orum Therapeutics has new funding data
Click to see if Orum Therapeutics had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at Orum Therapeutics
Find 2 more new buyers
Compare Similar Companies to Orum Therapeutics
Compare insights from companies similar to Orum Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Orum Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Orum Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Orum Therapeutics.
Orum Therapeutics financials insights
Gather financial insights about Orum Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Series A
$8M
2019
Series B
$30M
2021
Series B
$84M
Orum Therapeutics Tech Stack
A closer look at the technologies used by Orum Therapeutics
Most Recent Scoops
Event
Events, Engineering, Sales, Bioengineering, Laboratory Operations, Pharmaceuticals, Field /Outside Sales, Clinical Operations, Field Marketing, Operations
Left Company
Executive Move
Left Company
Executive Move
Orum Therapeutics has announced that Kim Jaewon, Chief Financial Officer, has left the organization to join VantAI as Chief Operating Officer & Chief Financial Officer.
Event
Events
Orum Therapeutics News & Media
Orum Therapeutics Submits Registration Statement for KOSDAQ Listing
DAEJEON, South Korea & BOSTON--(BUSINESS WIRE)-- #ADC--Orum Therapeutics Submits Registration Statement for KOSDAQ ListingOrum Therapeutics Announces a Global, Multi-Target License and Option Agreement with Vertex for the Use of Orum’s TPD²® Technology to Develop Novel Degrader-Antibody Conjugates
BOSTON & DAEJEON, South Korea--(BUSINESS WIRE)-- #ADC--A Global, Multi-Target License and Option Agreement with Vertex for the Use of Orum’s TPD²® Technology to Develop Novel Degrader-Antibody ConjugatesBMS buys Orum Therapeutics' ADC protein degrader for up to $180 million
The big pharma company Bristol Myers Squibb (BMS) committed up to $180 million for a phase 1-ready antibody-drug conjugate (ADC) for the treatment of blood cancer from the U.S.-South Korean biotech company Orum Therapeutics.Orum Therapeutics Announces Acquisition of ORM-6151 Program by Bristol Myers Squibb
BOSTON & DAEJEON, South Korea--(BUSINESS WIRE)-- #ADC--Orum Therapeutics Announces Acquisition of ORM-6151 Program by Bristol Myers Squibb
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Orum Therapeutics
Sign Up For FreeTo access detailed company insights
Orum Therapeutics is a clinical stage biotech company focused on pioneering a novel class of antibody-drug conjugates (ADCs) through their innovative protein degrader technology. Their approach aims to enhance the efficacy, safety, and half-life of conventional targeted protein degraders. The company is dedicated to expanding the landscape of drugg... Read More
